Depression-like phenotype following chronic CB1 receptor antagonism

Depression-like phenotype following chronic CB1 receptor antagonism

Rimonabant was the first clinically marketed cannabinoid (CB)1 receptor antagonist developed to treat obesity. Unfortunately, CB1 receptor antagonism produced adverse psychiatric events in patients. To determine whether this occurs pre-clinically, we investigated the effects of rimonabant in rodent...

Full description

Bibliographic Details
Main Authors:	Chad E. Beyer, Jason M. Dwyer, Michael J. Piesla, Brian J. Platt, Ru Shen, Zia Rahman, Karen Chan, Melissa T. Manners, Tarek A. Samad, Jeffrey D. Kennedy, Brendan Bingham, Garth T. Whiteside
Format:	Article
Language:	English
Published:	Elsevier 2010-08-01
Series:	Neurobiology of Disease
Subjects:	Cannabinoids Rimonabant Mood disorders Chronic mild stress Neurogenesis Cytokines
Online Access:	http://www.sciencedirect.com/science/article/pii/S0969996110000926

Similar Items

The CB1 receptor interacts with cereblon and drives cereblon deficiency-associated memory shortfalls
by: Carlos Costas-Insua, et al.
Published: (2024-03-01)

The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol
by: José Antonio López-Moreno, et al.
Published: (2007-02-01)

Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors
by: Adriano Mollica, et al.
Published: (2017-01-01)

The Impact of CB1 Receptor on Nuclear Receptors in Skeletal Muscle Cells
by: Mansour Haddad
Published: (2021-10-01)

The cannabinoid CB1 receptor and mTORC1 signalling pathways interact to modulate glucose homeostasis in mice
by: Francisco J. Bermudez-Silva, et al.
Published: (2016-01-01)

Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge
by: Omar Soler-Cedeno, et al.
Published: (2022-10-01)

Requiem for Rimonabant: Therapeutic Potential for Cannabinoid CB<sub>1</sub> Receptor Antagonists after the Fall
by: Taryn Bosquez-Berger, et al.
Published: (2023-08-01)

Discovery of Orexant and Anorexant Agents with Indazole Scaffold Endowed with Peripheral Antiedema Activity
by: Marilisa P. Dimmito, et al.
Published: (2019-09-01)

Effects of a Peripherally Restricted Hybrid Inhibitor of CB1 Receptors and iNOS on Alcohol Drinking Behavior and Alcohol-Induced Endotoxemia
by: Luis Santos-Molina, et al.
Published: (2021-08-01)

The Cannabinoid CB1 Antagonist TM38837 With Limited Penetrance to the Brain Shows Reduced Fear-Promoting Effects in Mice
by: Vincenzo Micale, et al.
Published: (2019-03-01)

CB1 receptor antagonist rimonabant protects against chronic intermittent hypoxia-induced renal injury in rats
by: Li Zhao, et al.
Published: (2021-04-01)

Influence of rimonabant treatment on peripheral blood mononuclear cells; flow cytometry analysis and gene expression profiling
by: Stefan Almestrand, et al.
Published: (2015-06-01)

Pharmacologic Antagonization of Cannabinoid Receptor 1 Improves Cholestasis in Abcb4-/- MiceSummary
by: Nora Helmrich, et al.
Published: (2022-01-01)

Pharmacological blockade of either, cannabinoid CB1 or CB2 receptors, prevents both cocaine-induced conditioned locomotion and cocaine-induced reduction of cell proliferation in the hippocampus of adult male rats.
by: EDUARDO eBLANCO-CALVO, et al.
Published: (2014-01-01)

Cannabinoid receptor-1 antagonism: a new perspective on treating a murine schistosomal liver fibrosis model
by: Yasmine Amr Issa, et al.

Context-dependent effects of the CB1 receptor antagonist rimonabant on morphine-induced behavioral sensitization in female mice
by: Eduardo A. V. Marinho, et al.
Published: (2023-02-01)

Maternal sevoflurane exposure induces neurotoxicity in offspring rats via the CB1R/CDK5/p-tau pathway
by: Yuxiao Wan, et al.
Published: (2023-01-01)

Targeting the Endocannabinoid/CB1 Receptor System For Treating Major Depression Through Antidepressant Activities of Curcumin and Dexanabinol-Loaded Solid Lipid Nanoparticles
by: Xiaolie He, et al.
Published: (2017-08-01)

Cannabinoids and Neurogenesis: The Promised Solution for Neurodegeneration?
by: Andrea Valeri, et al.
Published: (2021-10-01)

Rimonabant Kills Colon Cancer Stem Cells without Inducing Toxicity in Normal Colon Organoids
by: Donatella Fiore, et al.
Published: (2018-01-01)

Oral administration of the cannabigerol derivative VCE-003.2 promotes subventricular zone neurogenesis and protects against mutant huntingtin-induced neurodegeneration
by: José Aguareles, et al.
Published: (2019-03-01)

Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss
by: Alison J. Dawson, et al.
Published: (2017-07-01)

Pharmacologic antagonism of CB1 receptors improves electrophysiological alterations in Purkinje cells exposed to 3-AP
by: Hoda Ranjbar, et al.
Published: (2023-03-01)

Cannabinoids Modulate Neuronal Activity and Cancer by CB1 and CB2 Receptor-Independent Mechanisms
by: Ken Soderstrom, et al.
Published: (2017-10-01)

INVERSE AGONISTS: MORE THAN JUST ANTAGONISTS?
by: R. N. Alyautdin, et al.
Published: (2022-06-01)

Cannabinoid CB1 and CB2 Receptor-Mediated Arrestin Translocation: Species, Subtype, and Agonist-Dependence
by: Mikkel Søes Ibsen, et al.
Published: (2019-04-01)

Pharmacological Properties, Therapeutic Potential and Molecular Mechanisms of JWH133, a CB2 Receptor-Selective Agonist
by: Hebaallah Mamdouh Hashiesh, et al.
Published: (2021-07-01)

Interfering with reconsolidation by rimonabant results in blockade of heroin-associated memory
by: Jiang Lin, et al.
Published: (2024-03-01)

High fat-fed GPR55 null mice display impaired glucose tolerance without concomitant changes in energy balance or insulin sensitivity but are less responsive to the effects of the cannabinoids rimonabant or Δ(9)-tetrahydrocannabivarin on weight gain
by: Edward T. Wargent, et al.
Published: (2020-08-01)

Abdominal obesity, cardiometabolic risk and endocannabinoid system
by: G. Bittolo Bon
Published: (2013-05-01)

Potential Implications of Rimonabant on Age-Related Oxidative Stress and Inflammation
by: Renáta Szabó, et al.
Published: (2022-01-01)

Approved and Off-Label Uses of Obesity Medications, and Potential New Pharmacologic Treatment Options
by: Fernando Cordido, et al.
Published: (2010-01-01)

Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology
by: Rui S. Rodrigues, et al.
Published: (2019-04-01)

Can the benefits of cannabinoid receptor stimulation on neuroinflammation, neurogenesis and memory during normal aging be useful in AD prevention?
by: Marchalant Yannick, et al.
Published: (2012-01-01)

Positive Allosteric Modulation of CB1 and CB2 Cannabinoid Receptors Enhances the Neuroprotective Activity of a Dual CB1R/CB2R Orthosteric Agonist
by: Beatrice Polini, et al.
Published: (2020-12-01)

Antagonization of OX<sub>1</sub> Receptor Potentiates CB<sub>2</sub> Receptor Function in Microglia from APP<sub>Sw/Ind</sub> Mice Model
by: Iu Raïch, et al.
Published: (2022-10-01)

Hepatic expression of cannabinoid receptors CB1 and CB2 correlate with fibrogenesis in patients with chronic hepatitis B
by: Erhei Dai, et al.
Published: (2017-06-01)

Voltage dependence of the cannabinoid CB1 receptor
by: Esty Goldberger, et al.
Published: (2022-10-01)

Endocannabinoid engagement of CB2 regulates RSV-induced immunity
by: Barbara L. F. Kaplan
Published: (2018-12-01)

Rimonabant and Cannabidiol Rewrite the Interactions between Breast Cancer Cells and Tumor Microenvironment
by: Maria Chiara Proto, et al.
Published: (2023-08-01)